A mildly high total bilirubin with normal liver enzymes is usually Gilbert syndrome, not liver damage. At Longevity Benchmark, we write the guides that readers bring their panel results to, and a slightly flagged total bilirubin is one of the most frequent sources of unnecessary alarm we see.
The Verdict
Bilirubin Blood Test Normal Range and Reference Bands
Adult reference ranges for total bilirubin vary between testing laboratories and international measurement systems. In the United States, Labcorp establishes an adult reference interval of 0.0 to 1.2 mg/dL. In the United Kingdom, the Worcestershire Acute Hospitals NHS Trust reports an adult reference range of 5 to 21 µmol/L.
The standard conversion factor between these two systems is 17.1, as documented by the American Academy of Family Physicians (AAFP). Multiplying 1.2 mg/dL by 17.1 yields 20.5 µmol/L, meaning the upper thresholds of these systems align closely. The AAFP notes that clinical jaundice becomes visible only when serum bilirubin exceeds 3.0 mg/dL (51.3 µmol/L). A result flagged just above the reference limit still sits several times below the 3.0 mg/dL (51.3 µmol/L) at which yellowing becomes visible. Newborn bilirubin is a separate clinical topic with its own thresholds, handled by a paediatric clinician; this page covers adults only.
| Laboratory System | Reported Reference Interval | Converted Equivalent | Specimen and Methodology Notes |
|---|---|---|---|
| Labcorp (United States) | 0.0 to 1.2 mg/dL | 0.0 to 20.5 µmol/L | Adult interval for individuals aged one month and older. |
| Worcestershire Acute Hospitals NHS Trust (UK) | 5 to 21 µmol/L | ≈0.29 to 1.23 mg/dL (converted) | Serum sample collected in a 5 mL gold-top tube. |
| Clinical Jaundice Threshold (AAFP) | Exceeds 3.0 mg/dL | Exceeds 51.3 µmol/L | Concentration required for yellowing of sclera and skin. |
The Biological Origin of Bilirubin
Bilirubin is a yellowish compound produced during the continuous breakdown of haemoglobin from old red blood cells. According to the AAFP and a review in Clinical and Experimental Gastroenterology, an average adult produces approximately 250 mg of bilirubin per day through the catabolism of the haem molecule.
Circulating red blood cells provide roughly 75% to 80% of this daily output. Levitt and Levitt report that roughly 75% derives from circulating haemoglobin, with the remaining 25% coming from other haem compounds, primarily cytochromes. The AASLD Liver Fellow Network puts the erythrocyte contribution at 80% from senescent red cells.
The catabolic pathway begins inside reticuloendothelial macrophages, which degrade haem into biliverdin before reducing it into unconjugated bilirubin. Because unconjugated bilirubin is lipid-soluble, it passes into the bloodstream bound to serum albumin. Once delivered to hepatocytes, the enzyme uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1) attaches glucuronic acid molecules to form water-soluble conjugated bilirubin. The liver then secretes this conjugated form into bile, which drains into the digestive tract and exits in stool.
Gilbert Syndrome and Isolated Total Bilirubin Elevation
Gilbert syndrome is the commonest reason a healthy adult's total bilirubin reads mildly high while every other liver marker is normal. The AAFP describes it as a benign condition, and it is inherited rather than acquired. According to MedlinePlus Genetics, it affects 3% to 7% of Americans. The AAFP reports that it affects 10% of the white population. A review in Frontiers in Medicine places overall population prevalence at approximately 3% to 13%. In the UK Biobank, about 10% of participants (46,189 of 463,060 genotyped) were homozygous for rs887829-T, the genotype characterising Gilbert syndrome, yet only about 3% of those individuals had a formal clinical diagnosis recorded.
The underlying mechanism involves reduced hepatic conjugation capacity. MedlinePlus Genetics states that people with Gilbert syndrome possess approximately 30% of normal bilirubin-UGT enzyme activity. About 30% of affected individuals have no symptoms and discover their status only when routine panels return an elevated total bilirubin. The Frontiers in Medicine review describes the commonest variant, UGT1A1*28, as a TA insertion in the TATA box of the UGT1A1 promoter, producing the [A(TA)7TAA] genotype, and reports that this variant reduces UGT1A1 gene expression by 50% to 70%. In a genotyped clinical series, the frequency of the (TA)7TAA allele was 0.879 and the 7/7 genotype was 80% among patients, compared to 0.384 and 10% in controls, with mean unconjugated bilirubin measuring 2.5 ± 0.25 mg/dL versus 0.61 ± 0.09 mg/dL in controls.
In the Frontiers in Medicine 2025 review, total bilirubin in people with Gilbert syndrome falls within the range for Gilbert syndrome, under 100 µmol/L (5.8 mg/dL), while people with Crigler-Najjar syndrome type II, a rarer and more severe deficiency of the same enzyme, usually sit between 100 and 400 µmol/L. Those are descriptions of two diagnosed groups, not a cut-off you can read your own result against. Gilbert syndrome is a diagnosis of exclusion. It is reached by a clinician who has ruled out haemolysis, hepatitis and biliary obstruction first, which is why a result that looks like Gilbert syndrome is still a result to take to a doctor.
The Measurable Impact of Prolonged Fasting
Prolonged fasting significantly increases serum bilirubin concentrations in both healthy individuals and people with Gilbert syndrome. Levitt and Levitt report that unconjugated bilirubin rises 80% from a mean of 0.5 to 0.9 mg/dL in healthy subjects after a 48-hour fast. In individuals with Gilbert syndrome, the elevation is steeper, increasing 130% from 1.5 to 3.5 mg/dL under identical conditions.
Clinical laboratories recognise this physiological shift. Labcorp notes that fasting longer than 36 hours may moderately elevate total bilirubin. A classic caloric restriction study evaluated a protocol reducing intake to 400 kcal daily for 72 hours. In that investigation, an increase was usually visible within 24 hours of cutting calories. A rise of 100% or greater suggested unconjugated hyperbilirubinaemia from Gilbert syndrome, whereas in healthy comparison subjects unconjugated bilirubin remained below 1.0 mg/100 mL.
Everyday testing contexts differ from experimental fasts. Routine metabolic panels generally involve an overnight fast of 8 to 12 hours. While a physiological upward drift during an overnight fast is plausible, published studies evaluate only fasts of 24, 36, 48, or 72 hours, or extreme caloric restriction. The specific numerical impact of a standard 8 to 12 hour overnight fast remains unverified.
Other Clinical Causes of Raised Total Bilirubin
An elevated total bilirubin outside of Gilbert syndrome indicates accelerated haemolysis, hepatocellular injury, or physical obstruction of bile ducts. The AAFP groups the haemolytic causes into four kinds:
Haptoglobin is the companion test when haemolysis is suspected. The MedlinePlus haptoglobin guide notes that haptoglobin binds free haemoglobin released by ruptured red cells, and that a level lower than normal may be a sign of haemolytic anaemia, liver disease or a reaction to a transfusion. Clinicians read it alongside reticulocyte counts, haemoglobin, haematocrit, and lactate dehydrogenase. Normal red blood cells survive 120 days. Levitt and Levitt show that in a non-anaemic person, red cell survival must fall roughly 3.7-fold to 32 days before total bilirubin reaches 1.4 mg/dL. If anaemia cuts circulating haemoglobin by half, survival must fall 7.4-fold to 16 days to produce that same elevation.
Hepatocellular injury and biliary obstruction cause marked elevations. Labcorp notes that total bilirubin rises in viral hepatitis, cholangitis, cirrhosis, and biliary obstruction. Gallstones or strictures impede bile drainage, causing conjugated bilirubin to leak back into the circulation. Pharmaceuticals also alter clearance: Labcorp lists phenothiazines, oral contraceptives, and steroids. Antiretrovirals can inhibit conjugation directly. According to the FDA-approved label on DailyMed, atazanavir (REYATAZ) inhibits UGT1A1. In clinical study AI424-138, 44% of patients developed Grade 3 to 4 total bilirubin elevations at or above 2.6 times the upper limit of normal. The label states the hyperbilirubinaemia is reversible once REYATAZ is stopped.
- Red cell membrane disorders. Spherocytosis, elliptocytosis, and ovalocytosis.
- Red cell enzyme disorders. Glucose-6-phosphate dehydrogenase (G6PD) deficiency and pyruvate kinase deficiency.
- Haemoglobin disorders. Sickle cell anaemia and thalassaemia.
- Autoimmune haemolytic anaemia. Acquired red cell destruction, including drug-induced forms associated with approximately 150 therapeutic drugs.
| Clinical Etiology | Accompanying panel pattern | Diagnostic Context |
|---|---|---|
| Gilbert syndrome | Normal ALT, AST, ALP and GGT | Benign genetic variant in UGT1A1 promoter; commonest cause of isolated elevation. |
| Haemolytic anaemia | Low haptoglobin, raised reticulocytes, normal transaminases | Accelerated red blood cell destruction exceeding liver clearance capacity. |
| Biliary duct obstruction | Marked rise in ALP and GGT, dark urine, pale stool | Physical blockage of bile drainage by gallstones, strictures, or tumours. |
| Hepatocellular injury | Marked rise in ALT and AST | Active parenchymal damage from acute viral hepatitis, toxins, or cirrhosis. |
| Drug-induced UGT1A1 inhibition | Normal liver enzymes, resolves off the drug | Medications like atazanavir competing directly for glucuronidation enzymes. |
Physical Exertion and Daily Diurnal Rhythms
In 7,685 British middle-aged men, serum bilirubin fell steadily across the day, with mean values after 6 pm running 30% below morning values. That is the only cohort in which the size of the effect has been measured, so it is a finding about middle-aged men rather than a published figure for all adults. In that study, published in the Journal of Clinical Pathology, time of day accounted for more than 5% of between-subject variance for only three analytes: bilirubin, phosphate, and triglycerides.
Prolonged physical exertion also produces significant elevations in circulating bilirubin. A study published in PMC compared endurance running across three event distances: a standard 42.195 km marathon, a 100 km race, and a 308 km race. Total bilirubin increased significantly after the 100 km and 308 km courses, with the 308 km event generating significantly higher values than the standard marathon. The authors attributed this post-race rise to hemocytocatheresis, accelerated physiological turnover of haemoglobin, and mechanical foot-strike haemolysis rather than structural liver disease.
A within-subject CV of 21.8% means one person's own bilirubin moves substantially from draw to draw without anything changing in their liver. It is one of the few routine analytes where repeat testing on a second day is worth more than reacting to a single value. The Westgard biological variation database documents a within-subject coefficient of variation (CVI) of 21.8% and a between-subject variation (CVG) of 28.4% for total bilirubin in serum.
Low Bilirubin and the Causality Question
A low total bilirubin reading on a routine blood panel is rarely a sign of disease and does not require medical intervention. According to MedlinePlus, low bilirubin concentrations are not usually a cause for concern. They are occasionally observed in people taking medications such as antibiotics, birth control pills, sleeping pills, or seizure medicines.
Observational epidemiology frequently links higher baseline bilirubin concentrations with favourable metabolic and respiratory profiles. In an analysis of the UK Biobank cohort, of the 839 health outcomes examined, 418 (50%) showed some association with serum bilirubin at an unadjusted P<0.05 threshold. An association at that threshold, across that many outcomes, is what you would expect to find whether or not bilirubin does anything, which is why the authors went on to test the same outcomes genetically.
The genetic analyses failed to confirm a causal protective effect. When the UK Biobank and FinnGen researchers analysed genetic variants characterising Gilbert syndrome, evidence of association disappeared across cardiovascular disease and chronic obstructive pulmonary disease. The only condition showing a clear genetic association was cholelithiasis (gallstones), with an odds ratio of 1.16 (95% confidence interval 1.12 to 1.20, P=5.7×10⁻¹⁶). The authors concluded that bilirubin has no likely causal role in protection from cardiovascular disease or other key healthcare outcomes.
A Mendelian randomization analysis in the HAPI Heart Study reached a similar conclusion. The UGT1A1*28 promoter genotype accounted for 45% of the variation in serum bilirubin. While crude observational analysis showed an inverse association between bilirubin and body mass index (-1.5, p=0.003), that association flipped direction in the genetic Mendelian randomization analysis (0.6, p=0.28). The researchers concluded that observational correlations between bilirubin, body mass index, and cholesterol are likely explained by confounding factors.
Total Bilirubin in Preventive and Longevity Panels
Total bilirubin is routinely measured as one of 14 analytes in a comprehensive metabolic panel (CMP) and serves as an anchor marker in a standard hepatic function panel. A standard liver panel evaluates total bilirubin alongside albumin, total protein, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT).
Preventive health protocols examine bilirubin to ensure healthy hepatic excretion and screen for occult haemolysis or biliary stasis. While early longevity literature hypothesised that higher circulating bilirubin might act as a systemic antioxidant, the genetic analyses do not support that argument. The UK Biobank and FinnGen authors concluded that bilirubin has no likely causal role in protection from cardiovascular disease, chronic obstructive pulmonary disease or other key healthcare outcomes. Neither study looked at lifespan.
Clinical guidance does not define a longevity-optimal target for total bilirubin. Attempting to deliberately raise serum bilirubin lacks clinical foundation and increases the risk of gallstone formation. Its genuine utility in routine preventive testing is interpretive: identifying whether isolated hyperbilirubinaemia reflects a benign Gilbert genotype, and ensuring that any elevation accompanied by abnormal ALT, AST, or alkaline phosphatase receives prompt investigation.
Clinical Thresholds for Consulting a Physician
A raised bilirubin level requires professional evaluation whenever it is accompanied by physical symptoms, abnormal liver enzymes, or a continuous upward trajectory across repeated tests. Isolated mild elevations often reflect Gilbert syndrome, but confirming that requires excluding active disease first.
- Visible tissue jaundice. Yellowing of the sclera (the whites of the eyes) or skin, which occurs when serum bilirubin exceeds 3.0 mg/dL (51.3 µmol/L).
- Changes in excretory colour. The appearance of dark tea-coloured urine or pale, clay-coloured stools, which indicates obstruction of biliary drainage.
- Abnormal liver enzymes. Any bilirubin elevation paired with abnormal transaminases (ALT or AST) or cholestatic markers (ALP or GGT).
- Signs of accelerated haemolysis. Unexplained pallor, fatigue, or shortness of breath alongside low haptoglobin or a depressed haematocrit.
- A rising trend. A total bilirubin that climbs across repeated tests rather than moving up and down within its usual range.
- Accompanying systemic symptoms. Fever, right upper quadrant abdominal pain, persistent nausea, or unexplained weight loss.
Frequently Asked Questions
What does a bilirubin blood test measure?
A bilirubin blood test measures total bilirubin, a yellowish pigment produced when the body breaks down haem from old red blood cells. An average adult generates approximately 250 mg of bilirubin daily, with 75% to 80% derived from circulating red blood cells and the rest from other haem proteins like cytochromes. The liver processes this pigment using the enzyme UGT1A1 to make it water-soluble before excreting it into bile. The test evaluates liver clearance, biliary drainage, and red blood cell turnover.
What is a normal bilirubin level?
Normal reference ranges depend on the testing laboratory and the reporting units. In the United States, Labcorp defines the adult total bilirubin reference interval as 0.0 to 1.2 mg/dL. In the United Kingdom, NHS laboratories like Worcestershire Acute Hospitals NHS Trust publish an adult range of 5 to 21 µmol/L. Multiplying mg/dL by 17.1 converts the value to µmol/L. Clinical jaundice only becomes visible when levels exceed 3.0 mg/dL (51.3 µmol/L), well above standard lab cut-offs.
What does high bilirubin mean on a blood test?
High bilirubin indicates that pigment production exceeds the liver's clearance capacity, hepatic conjugation is reduced, or bile ducts are obstructed. When bilirubin is elevated alongside abnormal liver enzymes like ALT, AST, or ALP, it points toward hepatitis, cirrhosis, or gallstones. When total bilirubin is mildly elevated while all other liver enzymes and blood counts are normal, Gilbert syndrome is the commonest explanation. Gilbert syndrome is a diagnosis of exclusion made by a clinician who rules out other causes.
Why is my bilirubin high in a blood test?
A high bilirubin result has several recognised causes. In healthy adults with normal liver panels, the commonest cause is Gilbert syndrome, a benign genetic variation in the UGT1A1 gene. Physiological stressors like prolonged fasting, dehydration, intercurrent illness, strenuous exercise, and menstruation trigger elevations in people with this genotype. Other causes include liver conditions like viral hepatitis, bile duct obstruction from gallstones, accelerated red blood cell breakdown (haemolysis), and medications like phenothiazines, oral contraceptives, steroids, or atazanavir.
Does a bilirubin blood test require fasting?
A standalone bilirubin test does not strictly require fasting, but it is frequently drawn as part of a comprehensive metabolic panel where fasting for several hours is requested. Prolonged fasting of 24 to 48 hours is known to substantially raise bilirubin concentrations, increasing levels by 80% in healthy adults and 130% in people with Gilbert syndrome. However, whether a standard 8 to 12 hour overnight fast measurably raises total bilirubin remains unverified in clinical research.
What does low bilirubin mean on a blood test?
Low bilirubin is generally harmless and does not require medical follow-up. According to MedlinePlus, low levels are not a cause for concern but can occur in people taking medications like antibiotics, birth control pills, sleeping pills, or seizure drugs. While observational studies found correlations between higher bilirubin and lower rates of cardiovascular illness, large genetic analyses did not support a causal link. The UK Biobank and FinnGen authors concluded that bilirubin has no likely causal role in protection from cardiovascular disease or COPD, and an earlier Mendelian randomization study found that the observed associations between bilirubin, body mass index and cholesterol are likely explained by confounding.
Does a CBC show bilirubin levels?
A complete blood count (CBC) does not measure bilirubin. A CBC quantifies red blood cells, white blood cells, haemoglobin, haematocrit, and platelets. Bilirubin is measured on a comprehensive metabolic panel or a hepatic function panel. However, clinicians often review a CBC alongside bilirubin when evaluating anaemia or suspected haemolysis. If red blood cells are breaking down rapidly, a CBC shows depressed haematocrit or haemoglobin, while companion tests like haptoglobin drop. Gilbert syndrome remains a diagnosis of exclusion that requires ruling out haemolysis first.
Is high bilirubin always a liver problem?
An elevated bilirubin does not always indicate liver damage. Bilirubin also rises from pre-hepatic causes like haemolytic anaemia, where red blood cells break down faster than a healthy liver can process them, or post-hepatic causes like gallstones physically blocking the bile duct. Furthermore, the commonest cause of a mild elevation, Gilbert syndrome, involves an inherited variation in the UGT1A1 promoter that slows processing without causing structural liver damage or inflammation. A doctor confirms Gilbert syndrome by excluding hepatitis, obstruction, and haemolysis.